Sign in
Taking people in United StatesPhase 2

Tests two immunotherapy drugs before surgery for skin melanoma with lymph node spread

Tests pembrolizumab and talimogene laherparepvec before surgery in adults with melanoma.

Key facts

Who runs it
University of Louisville
Where
Louisville, United StatesSee the site
Trial code
Registry title
Neoadjuvant Combination Immunotherapy for Stage III Melanoma
Status
Recruiting
Phase
Phase 2
People taking part
28 people, planned
Started
3 Jul 2019
Expected to end
1 Jun 2028
Type of study
Interventional
Treatments tested
  • Pembrolizumab
  • Talimogene Laherparepvec
Record updated
2 May 2024

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with melanoma of the skin that has spread to nearby lymph nodes and can be removed by surgery. They get T-VEC and pembrolizumab before surgery.

Age
18 years or older
Sex
All sexes can join
Disease stage
Stage III melanoma of the skin that can be removed by surgery, with lymph node spread that can be seen or felt. The primary melanoma has been removed. There must be a measurable lymph node that can be injected. No spread to distant organs (M1).
Earlier treatment
People cannot have had T-VEC, any other oncolytic virus, pembrolizumab, or any other PD-1, PD-L1 or PD-L2 inhibitor before.
Biomarker or test result
BRAF mutant or wild type are both allowed. Mutation status is not needed to join.

Main reasons for not taking part

  • Spread to distant organs (metastatic, AJCC M1 disease)
  • Melanoma of the mucous membranes or the eye (mucosal or uveal)
  • Other cancers in the past 3 years, except non-melanoma skin cancer
  • Autoimmune disease needing treatment in the past two years, or clearly weakened immune system
  • Active herpes skin sores, or need for regular anti-herpes drugs such as acyclovir

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • 18 years of age, any race or sex, who have pathologically confirmed cutaneous melanoma
  • ECOG performance status of 0 or 1
  • Adequate hematologic, hepatic, renal and coagulation function
  • Must have measurable disease and have an injectable target lymph node for intralesional therapy administration
  • Primary melanoma has been resected
  • Pathologically confirmed resectable stage III disease, clinically apparent. Resectability is at the discretion of the treating surgeon who is a melanoma specialist
  • Stage III disease can be at time of diagnosis of primary melanoma or a recurrence after initial treatment of stage I-II disease
  • BRAF mutant or wild type allowed (mutations status not necessary for enrollment)
  • Signed, written informed consent

Who cannot take part

  • May not have been previously treated with T-VEC, any other oncolytic virus, pembrolizumab, or any other PD-1, PD-L1, or PD-L2 inhibitor
  • Must not have active herpetic skin lesions or prior complications of herpetic infection and must not require intermittent or chronic treatment with an anti-herpetic drug (e.g. acyclovir) other than intermittent topical use
  • Cannot have metastatic (AJCC M1) disease
  • No evidence of melanoma associated with immunodeficiency state or history or other malignancies (other than non-melanoma skin cancer) within the past 3 years
  • Must not have a history or evidence of symptomatic autoimmune pneumonitis, glomerulonephritis, vasculitis, or other symptomatic autoimmune disease, document history of autoimmune disease or syndrome requiring systemic treatment in the past two years (i.e. use of disease modifying agents, steroids, or immunosuppressive agents) except vitiligo or resolved childhood asthma/atopy, or evidence of clinically significant immunosuppression
  • No primary mucosal or uveal melanoma

Where in United States

  • University of LouisvilleLouisville, United StatesContact: Stacy BaumTaking people

About the trial

What the trial wants to find out

Determine safety and efficacy of pre-operative combination immunotherapy with Talimogene Laherparepvec (T-VEC)/Pembrolizumab given prior to complete lymph node dissection in resectable stage 3 cutaneous melanoma with clinically apparent lymph node metastases.

The group in the trial

  • Combination T-VEC/PembrolizumabTreatment being tested

    Pre-operative talimogene laherparepvec (T-VEC) with Pembrolizumab T-VEC - intra-lesional injection into palpable lymph nodes every 3 weeks for 6 months, or until complete response of target tumors. Pembrolizumab - administered intravenously every 3 weeks for 6 months, then every 3 weeks for one year in the adjuvant setting following complete lymph node dissection.

    Treatment: Pembrolizumab and Talimogene Laherparepvec

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Neoadjuvant Combination Immunotherapy for Stage III Melanoma
Plain-language title
Tests two immunotherapy drugs before surgery for skin melanoma with lymph node spreadGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
2 May 2024